Literature DB >> 33184871

Aberrant expression of HMB45 and negative PRAME expression in halo nevi.

Kristen N Ruby1, Zhongze Li2, Shaofeng Yan1.   

Abstract

BACKGROUND: Traditionally, most cutaneous nevi show a gradient of HMB45 (human melanoma black 45) and negative PRAME (preferentially expressed antigen in melanoma) immunostaining, while melanomas often show irregularly positive, diffusely positive or completely negative HMB45 expression, and PRAME immunopositivity. However, we have occasionally observed benign halo nevi with loss of HMB45 gradient, raising diagnostic consideration for melanoma. The purpose of this study was to elucidate the expression pattern of HMB45 and PRAME in nevi with the halo phenomenon (NHP).
METHODS: PRAME and HMB45 staining patterns in 20 cases of NHP and 16 cases of conventional nevi were evaluated using light microscopy. An HMB45 gradient was defined as immunopositivity in only superficial melanocytes. HMB45 aberrant expression consisted of superficial and deep immunopositivity.
RESULTS: Aberrant HMB45 expression was observed in 10 of 20 NHP (50%). A gradient of HMB45 staining was seen in most conventional nevi, with only one showing focal weak expression in the deep dermis (6.3%). All cases of NHP and conventional nevi showed essentially negative immunostaining by PRAME.
CONCLUSION: Aberrant HMB45 expression in NHP is not uncommon and may be a diagnostic pitfall. Negative PRAME immunostaining may be a reassuring finding to help differentiate halo nevus from malignant melanoma.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HMB45; PRAME; halo nevus; halo phenomenon

Year:  2020        PMID: 33184871     DOI: 10.1111/cup.13916

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  4 in total

Review 1.  Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.

Authors:  Costantino Ricci; Emi Dika; Francesca Ambrosi; Martina Lambertini; Giulia Veronesi; Corti Barbara
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

2.  HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).

Authors:  Marco Grillini; Costantino Ricci; Vincenzo Pino; Silvia Pedrini; Michelangelo Fiorentino; Barbara Corti
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-01-01

3.  PRAME expression is similar in scar and desmoplastic melanoma.

Authors:  Jaclyn M Plotzke; Nicholas A Zoumberos; Steven M Hrycaj; Paul W Harms; Scott C Bresler; May P Chan
Journal:  J Cutan Pathol       Date:  2022-07-11       Impact factor: 1.458

Review 4.  Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study.

Authors:  Gerardo Cazzato; Katia Mangialardi; Giovanni Falcicchio; Anna Colagrande; Giuseppe Ingravallo; Francesca Arezzo; Giovanna Giliberti; Irma Trilli; Vera Loizzi; Teresa Lettini; Sara Scarcella; Tiziana Annese; Paola Parente; Carmelo Lupo; Nadia Casatta; Eugenio Maiorano; Gennaro Cormio; Leonardo Resta; Domenico Ribatti
Journal:  Genes (Basel)       Date:  2022-03-19       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.